Evaluating Renal Benefits of Rivaroxaban Versus Vitamin K Antagonists in Atrial Fibrillation: A Systematic Review and Meta-analysis of Real-world Evidence.

For the remaining three subgroups, there was a trend towards a positive effect of rivaroxaban on declining eGFR outcomes; however, the differences versus VKAs did not reach statistical significance, with HRs of 0.54 (95% CI [0.23–1.29]; p=0.17; ∣ 2 =92%; Figure 3C ) for pre-existing kidney disease, 0.49 (95% CI [0.18– 1.31]; p=0.15; ∣ 2 =96%; Figure 3D ) for the elderly and 0.53 (95% CI [0.23– 1.24]; p=0.14; ∣ 2 =97%; Figure 3E ) for the Asian population.

also in 111,027 other papers